P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments

Written By Dean A. Wetherbee

https://www.prnewswire.com/news-releases/p4ml-becomes-founding-member-of-orphan-therapeutics-accelerator-otxl-to-support-broader-global-access-to-ultra-rare-disease-treatments-302696858.html?tc=eml_cleartime

Dean A. Wetherbee
Previous

AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases
Next

ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange - A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs